首页> 外文期刊>Expert opinion on biological therapy >Teduglutide in Crohn's disease
【24h】

Teduglutide in Crohn's disease

机译:特德鲁肽在克罗恩病中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: The currently available medications for treatment of Crohn's disease (CD) include aminosalicylates, corticosteroids, antibiotics, immunomo-dulators and biologic agents (infliximab, certolizumab pegol, adalimumab and natalizumab). These agents target the immune and inflammatory pathways of CD, while there is a shortage of agents that target the barrier functions of the gut that are impaired in CD. Glucagon-like peptide 2 is an enterogastrone with strong trophic effects on the intestinal mucosa. Teduglutide, the analog of glucagon-like peptide has been already approved by the US Food and Drug Administration as a treatment of short bowel syndrome. This review discusses the potential use of teduglutide in patients with CD. Areas covered: As there has been only one randomized placebo controlled trial of teduglutide in CD, there is a shortage of data regarding the efficacy of this agent in CD. The literature search was performed using Medline database with the use of the following key words: teduglutide, glucagon-like peptide-2, CD and inflammatory bowel disease. Expert opinion: Based on available data, it can be concluded that this agent seems to be a promising medication in CD and further trials are required to define the place of teduglutide in treatment of CD.
机译:简介:当前可用于治疗克罗恩氏病(CD)的药物包括氨基水杨酸酯,皮质类固醇,抗生素,免疫调节剂和生物制剂(英夫利昔单抗,赛妥珠单抗,阿达木单抗和那他珠单抗)。这些药物靶向CD的免疫和炎症途径,而缺乏靶向CD中受损的肠道屏障功能的药物。胰高血糖素样肽2是对肠粘膜具有强营养作用的肠胃泌素。 Teduglutide(胰高血糖素样肽的类似物)已被美国食品药品监督管理局批准用于治疗短肠综合征。这篇综述讨论了替丁鲁肽在CD患者中的潜在用途。涵盖的领域:由于CD中只有1种Teduglutide的随机安慰剂对照试验,因此关于CD中该药疗效的数据不足。使用Medline数据库使用以下关键词进行文献检索:特度鲁肽,胰高血糖素样肽2,CD和炎症性肠病。专家意见:根据现有数据,可以得出结论,这种药物似乎是CD的有希望的药物,需要进一步的试验来确定Teduglutide在CD治疗中的位置。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号